APA

Holthof L. C., van der Horst H. J., van Hal-van Veen S. E., Ruiter R. W. J., Li F., Buijze M., Andersen M. N., Yuan H., de Bruijn J., van de Donk N. W. C. J., Lokhorst H. M., Zweegman S., Groen R. W. J. & Mutis T. (20210427). Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. : Haematologica.

Chicago

Holthof Lisa C, van der Horst Hilma J, van Hal-van Veen Susan E, Ruiter Ruud W J, Li Fengzhi, Buijze Marijke, Andersen Morten N, Yuan Huipin, de Bruijn Joost, van de Donk Niels W C J, Lokhorst Henk M, Zweegman Sonja, Groen Richard W J and Mutis Tuna. 20210427. Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. : Haematologica.

Harvard

Holthof L. C., van der Horst H. J., van Hal-van Veen S. E., Ruiter R. W. J., Li F., Buijze M., Andersen M. N., Yuan H., de Bruijn J., van de Donk N. W. C. J., Lokhorst H. M., Zweegman S., Groen R. W. J. and Mutis T. (20210427). Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. : Haematologica.

MLA

Holthof Lisa C, van der Horst Hilma J, van Hal-van Veen Susan E, Ruiter Ruud W J, Li Fengzhi, Buijze Marijke, Andersen Morten N, Yuan Huipin, de Bruijn Joost, van de Donk Niels W C J, Lokhorst Henk M, Zweegman Sonja, Groen Richard W J and Mutis Tuna. Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. : Haematologica. 20210427.